Cell Valley Group was jointly founded by a group of passionate and visionary Chinese-American and Hong Kong-Chinese scientists. The founding team members come from world-class universities such as Harvard University, Cornell University, Columbia University, and the University of California, San Diego, bringing outstanding scientific research capabilities and an international perspective. The cutting-edge scientific concepts, deep academic foundations, and strong innovation capabilities gained from these top universities have laid a solid foundation for the development of Cell Valley Group.
Currently, Cell Valley Group has established a cell production center in Pingshan District, Shenzhen, a viral vector production center in Torch Development Zone, Zhongshan, and a northern R&D center in Daxing District, Beijing. The three wholly-owned subsidiaries—Shenzhen Cell Valley, Guangdong Junhou Biotech, and Beijing JingShen Cell Valley—form a strategic industrial layout covering both South and North China. The Group has built more than 10,000 square meters of GMP-grade manufacturing facilities and high-standard R&D laboratories and possesses two international-standard P2 biosafety laboratories in Shenzhen and Zhongshan.
Core technical strengths include:
China’s first clinical-grade retroviral vector GMP industrial production line (completed in 2020)
A library of more than 100 clinical-grade viral vectors
A globally leading eVLP-KOKI gene editing and delivery system
One of the first GMP-grade large-scale manufacturing lines in China for natural killer (NK) cell and γδ T-cell exosome production
These advantages position the Group as an industry leader.
On September 7, 2024, the Ministry of Commerce, the National Health Commission, and the National Medical Products Administration jointly issued the Notice on Launching Pilot Programs for Expanding Opening-Up in the Medical Field, which for the first time allowed foreign-invested enterprises in free trade zones such as Guangdong to engage in the R&D and application of technologies related to human stem cells, gene diagnostics, and gene therapy. As the first foreign (including Hong Kong)-funded enterprise to benefit from this policy, Cell Valley Group formally established ShenGang Cell Valley (Shenzhen) Medical Technology Co., Ltd. in the Qianhai Free Trade Zone of Shenzhen in February 2025, with a registered capital of RMB 100 million. Over 20% of its employees are from Hong Kong or the United States.
As the Group’s international business and medical service headquarters, ShenGang Cell Valley focuses on the Greater Bay Area, Southeast Asia, and Europe and North America, providing high-end cell and gene therapy solutions and actively expanding into consumer medical sectors such as healthcare and anti-aging. It has established an innovative "medical + consumer" dual-engine business model. Leveraging the Group's core technologies in clinical-grade viral vector preparation, gene editing and delivery systems, stem cell and immune cell platforms, and large-scale exosome manufacturing, ShenGang Cell Valley is committed to building a world-leading one-stop cell and gene therapy and health management service platform.
Shenzhen Cell Valley, as the Group's production and R&D headquarters, has been recognized as:
A major public service platform of Shenzhen's biopharmaceutical industry
The Viral Vector Generic Technology Research Platform of the National Engineering Research Center for Key Common Technologies in the Cell Industry
A base for the commercialization of innovation platforms under Shenzhen High-Tech Zone’s development special program
Vice President Unit of the China Association for the Promotion of Quality and Safety of Food and Drug Enterprises
Reliance unit for Shenzhen’s Special Fund for Medical Research
Vice Chairman Unit of the Shenzhen Biopharmaceutical Industry-Education Alliance
A 2023 Pingshan District Biopharmaceutical “Julong Leading Talent” D-class high-growth enterprise
A technology-based and innovation-oriented SME
Shenzhen Pingshan University Student Internship Base
It is also one of Shenzhen's newly announced "20+8" strategic emerging industry projects.
The project "One-stop Cell and Gene Therapy CRO/CDMO Service Platform – South China Cell Factory" by Shenzhen Cell Valley was approved as a major project of Shenzhen in 2022. Shenzhen Cell Valley has built GMP industrial production lines for retroviral vectors and cell products, GLP-standard process development and analytical laboratories, office spaces, smart exhibition halls, training classrooms, large conference rooms, and other multifunctional integrated production service platforms, covering a total area of 8,000 square meters, including 4,000 square meters of “C+A, B+A” cleanrooms.
The company operates production lines for CAR-T, CAR-NK, CAR-M, astrocyte, and other cell products, as well as production lines for various viral vectors (retrovirus, lentivirus, non-viral vectors, AAV), gene-engineered antibodies, cytokines, oncolytic viruses, exosomes, vaccines, and other drug-related cell raw materials.
Through partnerships with the National Engineering Research Center for Key Common Technologies in the Cell Industry and Shenzhen Polytechnic University, Shenzhen Cell Valley cultivates urgently needed high-end manufacturing and R&D talents for the cell industry in Shenzhen and the Greater Bay Area. It also works closely with drug regulatory authorities such as the Guangdong-Hong Kong-Macao Greater Bay Area Branch Center of the National Medical Products Administration’s Drug uation and Inspection, the Shenzhen Institute for Drug Control, as well as leading academic institutions such as Peking University, Tsinghua University, University of Science and Technology of China, and the Chinese Academy of Sciences.
Shenzhen Cell Valley has also formed deep collaborations with over 100 public and private tertiary hospitals, including Tongji Hospital of Huazhong University of Science and Technology, Beijing Children’s Hospital, Guangzhou Women and Children’s Medical Center, Xiangya Hospital of Central South University, Peking University Shenzhen Hospital, Nanshan District People’s Hospital of Shenzhen, Lu Daopei Medical Group, and Gaobo Medical Group, as well as with leading pharmaceutical companies such as Fosun Kite, InnoCare Pharma, BioGend, JW Therapeutics, and Hengrui Pharmaceuticals. It provides a professional and efficient one-stop service covering the entire process from early R&D, vector design, viral vector production, and cell production to IIT and IND application support.
Shenzhen Cell Valley is dedicated to addressing the critical bottlenecks in large-scale industrial production of cell and gene therapies in China. It is also committed to cultivating urgently needed professional talent in the field of cell and gene therapy, contributing to the healthy and rapid development of China’s cell and gene therapy industry.
Official WeChat Account Contact：Miss Sun
Mobile：+86 18810616095
Email：sunrui@sz-cell.com
Address：No.1 Rongtian Road, Jinsha Community, Kengzi Street, Pingshan District, Shenzhen
About Us
